Skip to content

Evaluation of Volume Status Changes in Children on Regular Hemodialysis at Assiut University Children,s Hospital

Evaluation of Volume Status Changes in Children on Regular Hemodialysis at Assiut University Children,s Hospital

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06194019
Enrollment
50
Registered
2024-01-08
Start date
2024-07-01
Completion date
2026-07-01
Last updated
2024-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Volume Status in Chronic Kidney Diseases

Brief summary

Chronic kidney disease (CKD) is a major health problem worldwide.(1) Chronic renal failure is defined as a decrease in glomerular filtration rate (GFR) of less than 60 ml/min/1.73 m2 of body surface evolving for more than 3 months

Detailed description

Chronic kidney disease (CKD) is a major health problem worldwide.(1) Chronic renal failure is defined as a decrease in glomerular filtration rate (GFR) of less than 60 ml/min/1.73 m2 of body surface evolving for more than 3 months . The etiologies of CKD in children are three main groups of pathologies: congenital anomalies of the kidney and urinary tract , hereditary nephropathies and acquired causes . (2) complication of pediatric hemodialysis is chronic fluid overload, left ventricular hypertrophy ,hypertension, heart failure, decrease arterial flexibility and often results in increase chance of morbidity and mortality, So fluid overload must be prevented .(3) Lung ultrasonography is the most recent, safe, easy, and reliable technique . The most commonly observed finding is a comet tail fanning out from the lung-wall interface and spreading upwards to the edge of the screen, named a B-line Chest sonar advantages include its noninvasiveness , ease of use, availability of portable machines, avoidance of radiation detect lung edema even in initial non symptomatic cases known as hidden lung congestion .(4) Bioimpedance analysis (BIA) Bio impedance spectroscopy (BIS) is a technique used to estimate total body water, extracellular water, lean and adipose tissue mass and over hydration . (5) N-terminal pro-brain natriuretic peptide is used as a biomarker to aid to predict cardiac dysfunction in children and adolescents .(6)it is an effective marker of volume status in patient with or without reduced ejection fraction undergoing hemodialysis. (7)

Interventions

N-terminal pro-brain natriuretic peptide (NT-proBNP) as a biomarker for detection volume overload.

Sponsors

Professor Mohamed mahrous Eltallawy
CollaboratorUNKNOWN
Assistant Professor Ahlam Badawy Ali
CollaboratorUNKNOWN
Lecturer Asmaa Ahmed Mahmoud
CollaboratorUNKNOWN
Assiut University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
3 Years to 18 Years

Inclusion criteria

\- Patients aged 3 to 16 years having end stage renal disease undergoing regular haemodialysis for at least more than 6 months of both gender were enrolled

Exclusion criteria

* Patients with chronic lung disease ,or pulmonary infection in the last 2 months were excluded from study. Patients with congestive heart failure Patients with Pulmonary edema Patient with pericardial effusion parental refusal to participate

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of volume status changes in children on regular hemodialysis at Assiut university children's hospitaltwo yearEvaluation of Volume status in children on regular haemodialysis by Chest sonar Evaluation of Volume status in children on regular haemodialysis by Chest sonar Evaluation of Volume status in children on regular haemodialysis by Chest sonar Evaluation of Volume status in children on regular haemodialysis by Chest sonar Evaluation of Volume status in children on regular haemodialysis by Chest sonar

Contacts

Primary ContactAhlam Abdelbaset, MD
Ahlam.Abdelbaset@med.aun.edu.eg01067815663
Backup ContactMohamed Mahrous, prof
Eltelawy270@aun.edu.eg01003486595

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026